Pentagon backs tech firm’s push to identify COVID-19 infections with body-worn sensors
The effort comes as experts worry about a “second wave” of the pandemic.
The Pentagon is working with a prominent technology company to use body-worn sensors to identify Americans infected with the novel coronavirus even before symptoms start to appear.
The nascent project, funded by the Defense Health Agency and organized by the Henry M. Jackson Foundation (HJF), also hopes to accurately predict which patients are likely to contract severe disease, according to a press release from physIQ, the Chicago-based company behind the effort.
“The second wave (of the pandemic) is going to come this fall. I’m already hearing people talk about, ‘How do I bring my employees back?'” Gary Conkright, physIQ’s founder and CEO, told ABC News. “We think we’re working on a solution to that.” Read more…
- PhysIQ announces FDA-sanctioned labeling to address the COVID-19 public health emergency with its proprietary Multivariate Change Index (MCI)
- Deployed within the pinpointIQ® continuous remote monitoring solution, physIQ’s MCI will be used to proactively monitor homebound patients with or vulnerable to COVID-19
- The sophisticated, machine learning-based algorithm uses multiple continuous vital signs from wearable sensors to detect subtle changes in physiology that may offer early detection of COVID-19-related clinical deterioration
CHICAGO, IL – The Food and Drug Administration (FDA) has sanctioned labeling for pinpointIQ®, physIQ’s continuous remote monitoring system for use in the COVID-19 pandemic, including application of its proprietary Multivariate Change Index (MCI). During this pandemic, pinpointIQ may be used to provide continuous physiologic remote monitoring to homebound or quarantined patients with confirmed or suspected COVID-19 or those whose high-risk profile that requires continuous remote monitoring, for example, those with heart failure, COPD, or hypertension. By passively collecting wearable sensor data and applying advanced analytics, pinpointIQ may ease burden on hospitals and other healthcare facilities and reduce the risk of exposure for patients and healthcare providers to SARS-CoV-2 and conserve resources for the very sickest. Read more…
- PhysIQ and the U.S. VA publish results of a clinical trial that demonstrates how artificial intelligence (AI) applied to continuous wearable sensor data may predict hospitalizations.
- When coupled with the high sensor wear compliance rates, the 7-10-day early warning timeframe suggests this approach has great promise to reduce hospitalization and improve quality of life of patients with heart failure.
- PhysIQ’s extensive IP portfolio and several FDA cleared AI-based algorithms paved the way for the results seen in this study.
CHICAGO, IL – physIQ, Inc. and the US Department of Veteran’s Affairs (VA) today published the results of a breakthrough study aimed at validating the ability to detect the onset of heart failure exacerbation using wearable sensors and machine learning-based personalized physiology analytics. Published in Circulation – Heart Failure, a journal of the American Heart Association, the LINK-HF study was designed to assess the ability to predict rehospitalization due to heart failure exacerbation using sophisticated analytics applied to continuous wearable sensor data. In the study, 100 patients were enrolled upon discharge from heart failure hospitalization across four VA hospitals and monitored continuously and for up to 90 days without intervention. Post hoc data analysis indicated a mean detection lead time of as high as 10.4 days prior to the hospitalization or ER visit with as high as 88% sensitivity and 86% specificity. Such a lead time interval should permit intervention aimed at preventing hospitalization. Read more…
Eighty percent of the cost of healthcare delivery in this country is attributed to chronic illness. What would happen if artificial intelligence applied to data from wearable technology could bend the cost curve by detecting subtle changes in patients’ health? Delivering the right personalized therapy to the right patient at the right time?
CEO of PhysIQ Gary Conkright has done just that. Gary and the team at PhysIQ have taken AI technology used to detect changes in jet airplane health and applied it to human physiology to help doctors proactively treat patients with chronic diseases. Hear how PhysIQ’s advancements have helped patients with Ebola and what Gary thinks chronic disease treatment will look like in the future.
Listen in to learn more about Gary and PhysIQ in the first episode of The Difference Makers.
Corvia Medical said it launched a heart failure device trial that will include the collection and analysis of data with PhysIQ’s continuous remote monitoring platform.
The Phase III trial is designed to evaluate the efficacy of Tewksbury, Mass.-based Corvia’s interatrial shunt in patients with heart failure. The randomized, controlled, double-blinded study includes plans to provide patients with a wearable biosensor and mobile data hub to establish a personalized pre-intervention baseline prior to randomization, then for 12 months after implantation.
CHICAGO – PhysIQ, a leader in applying artificial intelligence to wearable sensor data, today announced that it has received 510(k) clearance from the U.S. Food and Drug Administration (FDA) for their algorithm to continuously determine respiration rate in ambulatory patients. This clearance adds to their expanding portfolio of FDA-cleared cloud-based analytics, which also include QRS detection, heart rate, heart rate variability, atrial fibrillation detection, and their personalized physiology change detection analytic.
CHICAGO – PhysIQ, a leader in applying artificial intelligence to wearable sensor data, today announced that it has received 510(k) clearance from the U.S. Food and Drug Administration (FDA) for their algorithm to continuously determine respiration rate in ambulatory patients. This clearance adds to their expanding portfolio of FDA-cleared cloud-based analytics, which also include QRS detection, heart rate, heart rate variability, atrial fibrillation detection, and their personalized physiology change detection analytic.
This regulatory clearance is the company’s third, and like its predecessors uses artificial intelligence to characterize raw sensor data as actionable vital signs readings.
CHICAGO–(BUSINESS WIRE)–Feb 6, 2019–Omron Healthcare, Inc. and physIQ Inc. today announced a collaboration to integrate Omron’s innovative FDA-cleared device, HeartGuide ®, the first wearable blood pressure monitor into the pinpointIQ® platform to monitor at-risk patients in an outpatient setting. The strategic collaboration aims to generate actionable clinical information for at-risk patients in an outpatient environment by leveraging the complementary technologies of each company. Omron is the global leader in personal heart health and wellness technology and physIQ is a pioneer in FDA-cleared Artificial Intelligence physiology analytics.